What is the role of Argatroban in managing early neurological deterioration (END) following stroke?
Label:chem
Topic
Argatroban is a direct thrombin inhibitor that prevents fibrin formation, platelet aggregation, and the activation of coagulation factors V, VIII, XII, and protein C. It inactivates both free thrombin in the blood and thrombin bound to fibrin within thrombi, exerting potent antithrombotic effects. Argatroban has been shown to be effective and safe as an anticoagulant in patients with acute ischemic stroke.
From: "Argatroban plus dual antiplatelet therapy: Preliminary evidence for managing early neurological deterioration after lacunar stroke", Clinical Neurology and Neurosurgery, Volume 250, March 2025, 108786
Answer
Argatroban, when combined with dual antiplatelet therapy (DAPT), significantly improves neurological outcomes in patients with early neurological deterioration (END) following stroke. It reduces NIHSS scores and improves functional outcomes as measured by the modified Rankin Scale (mRS), with a favorable safety profile and no serious bleeding complications.
Return to Home
Chemical List
Knowledge you may be interested in